PMID- 11738306 OWN - NLM STAT- MEDLINE DCOM- 20020102 LR - 20191210 IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 38 IP - 7 DP - 2001 Dec TI - Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. PG - 1994-2000 AB - OBJECTIVES: This study was conducted to evaluate follow-up results in patients with hypertrophic obstructive cardiomyopathy (HOCM) who underwent either percutaneous transluminal septal myocardial ablation (PTSMA) or septal myectomy. BACKGROUND: Controversy exists with regard to these two forms of treatment for patients with HOCM. METHODS: Of 51 patients with HOCM treated, 25 were treated by PTSMA and 26 patients via myectomy. Two-dimensional echocardiograms were performed before both procedures, immediately afterwards and at a three-month follow-up. The New York Heart Association (NYHA) functional class was obtained before the procedures and at follow-up. RESULTS: Interventricular septal thickness was significantly reduced at follow-up in both groups (2.3 +/- 0.4 cm vs. 1.9 +/- 0.4 cm for septal ablation and 2.4 +/- 0.6 cm vs. 1.7 +/- 0.2 cm for myectomy, both p < 0.001). Estimated by continuous-wave Doppler, the resting pressure gradient (PG) across the left ventricular outflow tract (LVOT) significantly decreased immediately after the procedures in both groups (64 +/- 39 mm Hg vs. 28 +/- 29 mm Hg for PTSMA, 62 +/- 43 mm Hg vs. 7 +/- 7 mm Hg for myectomy, both p < 0.0001). At three-month follow-up, the resting PG remained lower in the PTSMA and myectomy groups (24 +/- 19 mm Hg and 11 +/- 6 mm Hg, respectively, vs. those before procedures, both p < 0.0001). The NYHA functional class was also significantly improved in both groups (3.5 +/- 0.5 vs. 1.9 +/- 0.7 for PTSMA, 3.3 +/- 0.5 vs. 1.5 +/- 0.7 for myectomy, both p < 0.0001). CONCLUSIONS: Both myectomy and PTSMA reduce LVOT obstruction and significantly improve NYHA functional class in patients with HOCM. However, there are benefits and drawbacks for each therapeutic method that must be counterbalanced when deciding on treatment for LVOT obstruction. FAU - Qin, J X AU - Qin JX AD - Cardiovascular Imaging Center, Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. FAU - Shiota, T AU - Shiota T FAU - Lever, H M AU - Lever HM FAU - Kapadia, S R AU - Kapadia SR FAU - Sitges, M AU - Sitges M FAU - Rubin, D N AU - Rubin DN FAU - Bauer, F AU - Bauer F FAU - Greenberg, N L AU - Greenberg NL FAU - Agler, D A AU - Agler DA FAU - Drinko, J K AU - Drinko JK FAU - Martin, M AU - Martin M FAU - Tuzcu, E M AU - Tuzcu EM FAU - Smedira, N G AU - Smedira NG FAU - Lytle, B AU - Lytle B FAU - Thomas, J D AU - Thomas JD LA - eng GR - R01 HL56688-01A1/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Adult MH - Aged MH - *Cardiac Catheterization MH - Cardiomyopathy, Hypertrophic/diagnostic imaging/*surgery MH - Echocardiography MH - Female MH - Follow-Up Studies MH - Heart Septum/diagnostic imaging/*surgery MH - Humans MH - Male MH - Middle Aged MH - *Minimally Invasive Surgical Procedures MH - Outcome and Process Assessment, Health Care MH - Postoperative Complications/diagnostic imaging MH - Ventricular Outflow Obstruction/diagnostic imaging/surgery OTO - NASA OT - NASA Discipline Cardiopulmonary OT - Non-NASA Center FIR - Thomas, J D IR - Thomas JD IRAD- Cleveland Clinic Found, OH EDAT- 2001/12/12 10:00 MHDA- 2002/01/05 10:01 CRDT- 2001/12/12 10:00 PHST- 2001/12/12 10:00 [pubmed] PHST- 2002/01/05 10:01 [medline] PHST- 2001/12/12 10:00 [entrez] AID - S0735109701016564 [pii] AID - 10.1016/s0735-1097(01)01656-4 [doi] PST - ppublish SO - J Am Coll Cardiol. 2001 Dec;38(7):1994-2000. doi: 10.1016/s0735-1097(01)01656-4.